Current State of CAR T-Cell Therapy in Chronic Lymphocytic Leukemia

Int J Mol Sci. 2021 May 24;22(11):5536. doi: 10.3390/ijms22115536.


Chimeric antigen receptor (CAR) T-cell therapy has already achieved remarkable remissions in some difficult-to-treat patients with B-cell malignancies. Although the clinical experience in chronic lymphocytic leukemia (CLL) patients is limited, the proportion of remissions reached in this disease is clearly the lowest from the spectrum of B-cell tumors. In this review, we discuss the antigenic targets exploited in CLL CAR-T therapy, the determinants of favorable responses, as well as the mechanisms of treatment failure specific to this disease.

Keywords: CD19; chimeric antigen receptor; chronic lymphocytic leukemia; immunotherapy.

Publication types

  • Review

MeSH terms

  • Antigens, CD19 / immunology*
  • B-Lymphocytes / immunology
  • Humans
  • Immunotherapy, Adoptive / methods*
  • Leukemia, Lymphocytic, Chronic, B-Cell / immunology*
  • Leukemia, Lymphocytic, Chronic, B-Cell / therapy*
  • Receptors, Chimeric Antigen / immunology*
  • Remission Induction
  • T-Lymphocytes / immunology


  • Antigens, CD19
  • CD19 molecule, human
  • Receptors, Chimeric Antigen